
浏览全部资源
扫码关注微信
1.新乡市中心医院/河南医药大学第四临床学院药学部,河南 新乡 453000
2.新乡市食品药品检验所,河南 新乡 453000
副主任药师。研究方向:医院药学。E-mail:wangyuefeng523@163.com
收稿:2025-05-16,
修回:2025-10-21,
录用:2025-10-23,
纸质出版:2025-11-30
移动端阅览
王月峰,高强,秦柯.肺炎支原体肺炎患儿药物治疗安全性的主动监测及影响因素 研究 Δ[J].中国药房,2025,36(22):2838-2844.
WANG Yuefeng,GAO Qiang,QIN Ke.Active surveillance of drug safety and influential factors in pediatric patients with Mycoplasma pneumoniae pneumonia[J].ZHONGGUO YAOFANG,2025,36(22):2838-2844.
王月峰,高强,秦柯.肺炎支原体肺炎患儿药物治疗安全性的主动监测及影响因素 研究 Δ[J].中国药房,2025,36(22):2838-2844. DOI: 10.6039/j.issn.1001-0408.2025.22.15.
WANG Yuefeng,GAO Qiang,QIN Ke.Active surveillance of drug safety and influential factors in pediatric patients with Mycoplasma pneumoniae pneumonia[J].ZHONGGUO YAOFANG,2025,36(22):2838-2844. DOI: 10.6039/j.issn.1001-0408.2025.22.15.
目的
2
分析肺炎支原体肺炎(MPP)患儿药品不良反应(ADR)的发生情况,并探讨其影响因素。
方法
2
从医院信息系统提取2023年10月1日-2024年9月30日新乡市中心医院(简称“我院”)收治的MPP患儿的病历资料,使用全面触发工具(GTT)进行回顾性审查,对触发器阳性患儿进行ADR判定,并分析其ADR发生特点。将患儿分为发生ADR组和未发生ADR组,通过单因素分析、多因素Logistic回归分析探讨MPP患儿发生ADR的潜在影响因素。
结果
2
共纳入MPP患儿1 325例;设计触发器条目24项,其中14项检出阳性,触发器阳性率为58.3%;触发器阳性1 301例次,所涉患儿846例;经判定,372例患儿发生399例次ADR,触发器阳性预测值为30.7%。ADR以血细胞异常(230例次,57.6%)、皮肤及其附件损害(78例次,19.5%)和胃肠系统损害(42例次,10.5%)为主,分别多发生在用药后4 d及以上、2~3 d、2~3 d;好发于>3~10岁患儿(295例,79.3%);与ADR发生相关的药品主要有静脉用激素药物(209频次)、头孢菌素类药物(180频次)、大环内酯类药物(38频次)、四环素类药物(28频次)和中药注射剂(28频次)。ADR类型中,严重的有1例次,一般的有394例次,新的有4例次;与药物的因果关系中,肯定的有1例次,很可能的有19例次,可能的有379例次;ADR结局中,痊愈的有151例次,不详的有248例次。单因素和多因素Logistic回归分析显示,过敏史[比值比=5.231,95%置信区间(2.004,13.656),
P
<0.05
]
、药物使用数量[比值比=1.064,95%置信区间(1.027,1.103),
P
<0.05
]
、静脉使用激素[比值比=3.223,95%置信区间(2.341,4.437),
P
<0.05
]
是MPP患儿ADR发生的独立危险因素,阿奇霉素的使用[比值比=0.544,95%置信区间(0.376,0.786),
P
<0.05
]
为MPP患儿ADR发生的独立保护因素。
结论
2
我院MPP患儿ADR发生率较高,主要包括血细胞异常、皮肤及其附件损害、胃肠系统损害;过敏史、药物使用数量、静脉使用激素、使用阿奇霉素与MPP患儿ADR的发生相关。
OBJECTIVE
2
To analyze adverse drug reactions (ADRs) in pediatric patients
with
Mycoplasma pneumoniae
pneumonia (MPP), and investigate the influential factors associated with the occurrence of ADRs.
METHODS
2
Clinical records of pediatric patients with MPP in Xinxiang Central Hospital (hereinafter referred to as “our hospital”) from Oct. 1st, 2023 to Sept. 30th, 2024 collected from the Hospital Information System were retrospectively reviewed using the global trigger tool (GTT). The positive triggers were further reviewed to confirm the occurrence of ADRs, and the characteristics of those ADRs were analyzed. The children were divided into the ADR group and the non-ADR group. Univariate analysis and multivariate Logistic regression analysis were performed to investigate the potential influential factors for ADRs in MPP children.
RESULTS
2
A total of 1 325 MPP children were included. Out of 24 designed triggers, 14 were positive, with a positive trigger rate of 58.3%. There were 1 301 positive trigger cases, involving 846 pediatric patients. After assessment, 399 cases of ADRs were identified in 372 pediatric patients, yielding a positive predictive value of triggers at 30.7%. The main types of ADRs were abnormal blood cells (230 cases, 57.6%), skin and its appendages damage (78 cases, 19.5%), and gastrointestinal system damage (42 cases, 10.5%), which predominantly occurred 4 days or more, within 2-3 days and within 2-3 days after medication, respectively. They were more prevalent in pediatric patients aged>3-10 years (295 cases, 79.3%). The major categories of drugs associated with ADRs included intravenous corticosteroids (209 cases), cephalosporins (180 cases), macrolides (38 cases), tetracyclines (28 cases) and traditional Chinese medicine (TCM) injections (28 cases). These ADR reports were classified into 3 types: 1 serious case, 394 general cases and 4 new cases. In terms of causality assessment, 1 case was assessed as certain, 19 cases as probable, and 379 cases as possible. In terms of ADR outcomes, 151 c
ases fully recovered, while the outcomes for 248 cases remained unknown. Univariate analysis and multivariate Logistic regression analysis revealed that a history of allergies [OR=5.231, 95%CI (2.004, 13.656),
P
<0.05
]
, the number of medications used [OR=1.064, 95%CI (1.027, 1.103),
P
<0.05
]
, and intravenous corticosteroid administration [OR=3.223, 95%CI (2.341, 4.437),
P
<0.05
]
were independent risk factors of ADRs in pediatric patients with MPP. The use of azithromycin [OR=0.544, 95%CI (0.376, 0.786),
P
<0.05
]
was identified as an independent protective factor against the occurrence of ADRs in pediatric patients with MPP.
CONCLUSIONS
2
Children with MPP in our hospital exhibit a higher incidence of ADRs, primarily involving abnormal blood cells, skin and its appendages damage, and gastrointestinal system damage. A history of allergies, the number of medications used, intravenous corticosteroid administration, and the use of azithromycin are associated with the occurrence of ADR in MPP pediatric patients.
国家卫生健康委员会 . 儿童肺炎支原体肺炎诊疗指南:2023年版 [J ] . 全科医学临床与教育 , 2023 , 21 ( 3 ): 196 - 202 .
刘凯 , 付红敏 , 陆权 . 儿童肺炎支原体肺炎的流行病学新进展 [J ] . 中华儿科杂志 , 2024 , 62 ( 7 ): 696 - 699 .
贾兆广 , 徐文帅 , 季丽娜 , 等 . 儿童肺炎支原体肺炎的临床诊疗及相关药物合理使用 [J ] . 中国药物警戒 , 2023 , 20 ( 12 ): 1391 - 1395 .
吴晓燕 , 张海霞 , 葛卫红 . 我院药品不良反应/事件主动监测系统构建 [J ] . 中国医院药学杂志 , 2020 , 40 ( 4 ): 437 - 442 .
王璐 , 黄哲 . 真实世界证据改善儿童药物临床试验障碍的对策研究 [J ] . 中国新药杂志 , 2022 , 31 ( 19 ): 1872 - 1875 .
Institute for Healthcare Improvement . IHI global trigger tool for measuring adverse events:second edition [EB/OL ] .[ 2025-04-30 ] . https://www.ihi.org/library/white-papers/ihi-global-trigger-tool-measuring-adverse-events_hsenc=p2AN-qtz--3UhKRyJow30c6gjwWp8Ut8vJz3Su9JpLWLk1JT3-FDuj-DrfzkMr_5A0_p#downloads https://www.ihi.org/library/white-papers/ihi-global-trigger-tool-measuring-adverse-events_hsenc=p2AN-qtz--3UhKRyJow30c6gjwWp8Ut8vJz3Su9JpLWLk1JT3-FDuj-DrfzkMr_5A0_p#downloads .
LIU Y , YAN J F , XIE Y F , et al . Establishment of a pedia-tric trigger tool based on Global Trigger Tool to identify adverse drug events of children:experience in a Chinese hospital [J ] . BMC Pediatr , 2020 , 20 ( 1 ): 454 .
北京协和医院世界卫生组织国际分类家族合作中心 . 疾病和有关健康问题的国际统计分类第十次修订本:第一卷 [M ] . 2版 . 北京 : 人民卫生出版社 , 2008 : 1 - 1248 .
World Health Organization-Uppsala Monitoring Centre . The use of the WHO-UMC system for standardized case causality assessment [EB/OL ] . [ 2025-04-30 ] . https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf .
国家药品不良反应监测中心 . WHO药品不良反应术语集 [M ] . 北京 : 中国医药科学技术出版社 , 2003 : 1 - 103 .
国家市场监督管理总局 . 药品不良反应报告和监测管理办法 [EB/OL ] . [ 2025-04-30 ] . http://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_eb5331517f7b4ed6b31b-1bc5e816b88a.html http://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_eb5331517f7b4ed6b31b-1bc5e816b88a.html .
张传洲 . 住院患儿药物不良反应调查预警及影响因素研究 [D ] . 青岛 : 青岛大学 , 2020 .
国家药品监督管理局药品评价中心 , 国家药品不良反应监测中心 . 国家药品不良反应监测年度报告:2023 年[EB/OL ] . [ 2025-04-30 ] . http://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_sjbg/202403/t20240326_50614.html http://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_sjbg/202403/t20240326_50614.html .
刘敏 , 张莹 , 赵楚洋 , 等 . 某院348例儿童药品不良反应Pareto最优分析 [J ] . 儿科药学杂志 , 2021 , 27 ( 5 ): 49 - 52 .
刘畅 , 林慧君 , 申红霞 , 等 . 某三甲儿童医院住院患者静脉用药不良反应的分析 [J ] . 中国药物警戒 , 2022 , 19 ( 7 ): 762 - 766 .
杨宝峰 , 陈建国 . 药理学 [M ] . 9版 . 北京 : 人民卫生出版社 , 2018 : 328 - 331 .
杨林勇 , 刘新社 , 萧伟 , 等 . 我国常见儿童药物不良反应及对策研究 [J ] . 中国中药杂志 , 2016 , 41 ( 14 ): 2743 - 2747 .
李黎明 , 李文武 . 中药制剂致613例严重不良反应报告分析 [J ] . 中国药房 , 2014 , 25 ( 27 ): 2572 - 2574 .
邢亚兵 , 张淼 , 李燕 . 2017-2019年某儿童医院药品不良反应/事件发生状况分析 [J ] . 中国合理用药探索 , 2021 , 18 ( 8 ): 33 - 37 .
KOJIMA T , MATSUI T , SUZUKI Y , et al . Risk factors for adverse drug reactions in older inpatients of geriatric wards at admission:multicenter study [J ] . Geriatr Gerontol Int , 2020 , 20 ( 2 ): 144 - 149 .
SHIRZAD-YAZDI N , TAHERI S , VAZIN A , et al . Drug-related problems among pediatric intensive care units:prevalence,risk factors,and clinical pharmacists’ interventions [J ] . BMC Pediatr , 2024 , 24 ( 1 ): 714 .
李洪燕 . 464例发生药品不良反应患儿中超说明书用药情况分析 [D ] . 重庆 : 重庆医科大学 , 2016 .
PEDRÓS C , QUINTANA B , REBOLLEDO M , et al . Prevalence,risk factors and main features of adverse drug reactions leading to hospital admission [J ] . Eur J Clin Pharmacol , 2014 , 70 ( 3 ): 361 - 367 .
SCHMITT A M , WALTER M , HERBRAND A K , et al . Characteristics and survival of patients with cancer with intended off-label use:a cohort study [J ] . BMJ Open , 2022 , 12 ( 5 ): e060453 .
刘玉军 . 静脉用阿奇霉素儿科临床用药安全性5年回顾分析 [D ] . 石家庄 : 河北医科大学 , 2020 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621